

July 29, 2025

To The Manager, Listing Department National Stock Exchange of India Ltd. Plot no. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai- 400 051 Symbol: BLISSGVS	To The General Manager, Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 506197
--	--

Subject: Outcome of Board Meeting held on Tuesday, July 29, 2025

Dear Sir/Madam,

We would like to inform you that, the Board Meeting of the Company was held today i.e. on Tuesday, July 29, 2025 at the registered office of the Company. In pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the following matter amongst others:

1. The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2025. A copy of unaudited standalone and consolidated financial results along with the Limited Review Report of the Auditors are enclosed herein below.

The Board of Directors meeting commenced at 01:00 p.m. and concluded at 4:30 p.m.

Kindly take the above information on your record and acknowledge it.

Thanking you.

Yours Faithfully,

For **Bliss GVS Pharma Limited**

Aditi Bhatt
Company Secretary

Encl: As above

Regd. Office : 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930,

Email : info@blissgvs.com • Website : www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory : Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.

Tel. (+91) (02525) 252713 • Fax : (+91) (02525) 255257. • Email : factory@blissgvs.com

Sr. No.	Particulars	Standalone				Consolidated			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		June 30, 2025	Mar 31, 2025	June 30, 2024	Mar 31, 2025	June 30, 2025	Mar 31, 2025	June 30, 2024	Mar 31, 2025
		Un-Audited	Audited (Refer Note 7)	Un-Audited	Audited	Un-Audited	Audited (Refer Note 7)	Un-Audited	Audited
I	Revenue from Operations	16,336.43	15,600.24	14,896.29	66,720.46	20,746.92	19,798.58	18,364.27	80,972.62
II	Other Income	1,059.27	936.08	684.09	3,621.65	3,545.40	1,206.85	412.27	3,649.35
III	Total Income (I+II)	17,395.70	16,536.32	15,580.38	70,342.11	24,292.32	21,005.43	18,776.54	84,621.97
IV	Expenses								
a.	Cost of Materials consumed	8,884.83	6,878.59	9,109.80	33,947.44	9,341.23	7,661.21	9,847.90	37,251.39
b.	Purchase of Stock-in-Trade	-	-	-	-	2,057.47	1,352.97	490.00	4,928.50
c.	Changes in inventories of work in process, finished goods and stock in trade	(1,720.56)	918.83	(1,992.30)	663.23	(2,209.55)	928.63	(1,823.95)	(811.07)
d.	Employee Benefits Expenses	2,810.04	2,522.46	2,351.69	9,941.78	3,100.26	2,824.38	2,653.90	11,205.04
e.	Finance Costs	511.23	129.98	116.80	658.38	547.15	167.79	153.10	812.00
f.	Depreciation and Amortisation Expenses	768.46	743.45	626.10	2,704.72	820.13	803.61	684.91	2,941.76
g.	Other Expenses	3,085.39	3,907.34	2,752.93	13,009.45	4,324.54	4,922.79	3,763.33	15,730.43
	Total Expenses	14,339.39	15,100.65	12,965.02	60,925.00	17,981.23	18,661.38	15,769.19	72,058.05
V	Profit before exceptional Items and tax (III-IV)	3,056.31	1,435.67	2,615.36	9,417.11	6,311.09	2,344.05	3,007.35	12,563.92
VI	Exceptional Items	-	-	-	-	-	-	-	-
VII	Profit/ (Loss) before Tax (V-VI)	3,056.31	1,435.67	2,615.36	9,417.11	6,311.09	2,344.05	3,007.35	12,563.92
VIII	Tax Expenses								
i.	Current Tax	1,149.69	467.92	704.41	3,073.77	1,944.28	662.57	864.77	4,012.73
ii.	Deferred Tax	(303.88)	(104.43)	(29.46)	(478.90)	(174.53)	89.26	(66.50)	(399.18)
iii.	Short/ (Excess) Provision of earlier years	105.21	(73.03)	(1.60)	(74.63)	105.21	(73.04)	(1.60)	(75.16)
IX	Net Profit/ (Loss) for the period (VII-VIII)	2,105.29	1,145.21	1,942.01	6,896.87	4,436.13	1,665.26	2,210.68	9,025.53
X	Other Comprehensive Income								
i.	Items that will not be reclassified to profit or loss								
(i)	Remeasurement of the defined benefit liabilities/ (assets)	(12.73)	(19.07)	(17.04)	(74.45)	(12.73)	(20.57)	(17.04)	(75.95)
(ii)	Income tax on remeasurement of defined benefits liabilities/ (assets)	3.20	4.79	4.29	18.73	3.20	5.17	4.29	19.11
ii.	Items that will be reclassified to profit or loss								
(i)	Exchange differences in translating the financial statements of foreign operations	-	-	-	-	794.77	(45.15)	21.47	(237.99)
(ii)	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	(200.03)	11.73	(5.40)	60.27
XI	Total Comprehensive Income / (Loss) for the period	2,095.76	1,130.93	1,929.26	6,841.15	5,021.34	1,616.44	2,214.00	8,790.97
XII	Profit attributable to :								
i.	Owners of the Company	-	-	-	-	4,303.79	1,553.91	2,069.74	8,429.93
ii.	Non-controlling interests	-	-	-	-	132.34	111.35	140.94	595.60
XIII	Other Comprehensive Income/ (Loss) attributable to :								
i.	Owners of the Company	-	-	-	-	585.21	(51.63)	3.32	(212.44)
ii.	Non-controlling interests	-	-	-	-	-	2.81	-	(22.12)
XIV	Total Comprehensive Income/ (Loss) attributable to :								
i.	Owners of the Company	-	-	-	-	4,889.00	1,502.28	2,073.06	8,217.49
ii.	Non-controlling interests	-	-	-	-	132.34	114.16	140.94	573.48
XV	Paid up equity share capital (Face Value - ₹ 1/- each)	1,054.98	1,053.70	1,048.83	1,053.70	1,054.98	1,053.70	1,048.83	1,053.70
XVI	Other Equity	-	-	-	1,04,809.61	-	-	-	1,03,983.86
XVII	Earnings Per Share Basic & Diluted (Not Annualised) (₹)								
i.	Basic	2.00	1.08	1.85	6.56	4.08	1.47	1.97	8.02
ii.	Diluted	1.98	1.07	1.81	6.50	4.04	1.46	1.93	7.95



Notes :

- 1 The above unaudited financial results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on July 29, 2025. These unaudited financial results have been prepared in accordance with recognition and measurement principles of Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and the other accounting principles generally accepted in India.
- 2 The above unaudited financial results for the quarter ended June 30, 2025 are prepared in compliance with the Ind AS which have been subjected to a limited review by the statutory auditors of the Company. The statutory auditors, Kalyaniwalla & Mistry LLP have issued limited review reports with unmodified conclusion on the standalone and consolidated unaudited financial results.
- 3 As the Company's business activity falls within a single operating segment viz "Pharmaceutical and Healthcare", no segment information is disclosed.
- 4 Employee Benefit Expenses includes Share Based Payment expense on account of ESOP Scheme, 2019 of ₹ 140.07 Lakh (quarter ended June 30, 2024 ₹ 129.40 Lakh) as per Ind AS 102 "Share based Payment" for the quarter ended June 30, 2025.
- 5 During the quarter ended June 30, 2025, the Company has allotted 1,27,250 equity shares of ₹ 1 each fully paid, on exercise of stock options by employees in accordance with the Company's ESOP Scheme, 2019. The outstanding number of options as at June 30, 2025 are 17,16,250.
- 6 The Board of Directors in its meeting held on May 12, 2025 has approved the sale of 51% stake in its step-down subsidiary, Greenlife Bliss Healthcare Ltd, Nigeria, held by its subsidiary, Bliss GVS International Pte Ltd, Singapore, to non-controlling shareholder for a total consideration of USD 13,00,000 subject to necessary regulatory and other approvals. Since the Company has lost control on Greenlife Bliss Healthcare Ltd. w.e.f April 01, 2025, the said Company has not been considered for consolidation.
- 7 The figures for the quarter ended March 31, 2025 are the balancing figures between audited figures in respect of the full financial year and the published year to date unaudited figures upto the third quarter of the previous financial year, which were subject to limited review.

For BLISS GVS PHARMA LIMITED

Place : Mumbai
Date : July 29, 2025




Gagan Harsh Sharma
Managing Director
DIN : 07939421

KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

REVIEW REPORT

TO THE BOARD OF DIRECTORS BLISS GVS PHARMA LIMITED

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Bliss GVS Pharma Limited** (“the Company”) for the quarter ended June 30, 2025, (“the Statement”) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, duly initialled by us for identification.
2. This Statement which is the responsibility of the Company’s Management and reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on July 29, 2025, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under section 133 of the Companies Act, 2013, read with relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. Attention is drawn to the fact that the figures for the quarter ended March 31, 2025, as reported in the Statement are the balancing figures between audited figures in respect of the full financial year ended March 31, 2025, and published year to date figures up to the end of the third quarter of the previous financial year, which were reviewed by us and not subject to audit.

Our conclusion on the Statement is not modified in respect of the above matter.

For **KALYANIWALLA & MISTRY LLP**
CHARTERED ACCOUNTANTS

Firm Regn. No.: 104607W / W100166


Jamshed K. Udawadia
PARTNER

M. No.: 124658

UDIN: 25124658BMJKEF1182

Mumbai: July 29, 2025



LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001
TEL.: (91) (22) 6158 6200. 6158 7200 FAX : (91) (22) 6158 6275

KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

REVIEW REPORT

TO THE BOARD OF DIRECTORS BLISS GVS PHARMA LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Bliss GVS Pharma Limited** (“the Parent”) and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”), for the quarter ended June 30, 2025, (“the Statement”) attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, duly initialled by us for identification.
2. This Statement, which is the responsibility of the Parent’s Management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
 - A. **Incorporated in India:**
 1. Kremoint Pharma Private Limited
 - 1.1 Eipii Exports Private Limited (Subsidiary of 1. above)
 - B. **Incorporated outside India:**
 2. Bliss GVS International Pte. Ltd., Singapore
 - 2.1 Asterisk Lifesciences (GH) Limited, Ghana (Subsidiary of 2. above)
 3. Asterisk Lifesciences Limited (UK), United Kingdom
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that



LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001

TEL : (01) (22) 6158 6200 6158 7200 FAX : (01) (22) 6158 6275

the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of 5 subsidiaries included in the Unaudited Consolidated Financial Results, whose interim financial information reflect the under mentioned items, before consolidation adjustments as considered in the Unaudited Consolidated Financial Results. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Parent's Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.


Particulars	Quarter Ended June 30, 2025 (Rs. in Lakh)
Total Revenue	5,477.04
Profit After Tax	2,162.87
Total Comprehensive Income	2,873.72

7. Attention is drawn to the fact that the figures for the quarter ended March 31, 2025, as reported in the Statement are the balancing figures between audited figures in respect of the full financial year ended March 31, 2025 and published year to date figures up to the end of the third quarter of the previous financial year, which were reviewed by us and not subject to audit.

Our conclusion on the Statement is not modified in respect of the above matters.

**For KALYANIWALLA & MISTRY LLP
CHARTERED ACCOUNTANTS**

Firm Registration No. 104607W/W100166


**Jamshed K. Udawadia
PARTNER**

M. No.: 124658

UDIN: 25124658BMJKEG6079

Mumbai, July 29, 2025

